IL307762A - Vaccine against viruses - Google Patents

Vaccine against viruses

Info

Publication number
IL307762A
IL307762A IL307762A IL30776223A IL307762A IL 307762 A IL307762 A IL 307762A IL 307762 A IL307762 A IL 307762A IL 30776223 A IL30776223 A IL 30776223A IL 307762 A IL307762 A IL 307762A
Authority
IL
Israel
Prior art keywords
amino acid
virus protein
modified
virus
parental
Prior art date
Application number
IL307762A
Other languages
English (en)
Hebrew (he)
Inventor
Ugur Sahin
Alexander Muik
Original Assignee
BioNTech SE
Ugur Sahin
Alexander Muik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE, Ugur Sahin, Alexander Muik filed Critical BioNTech SE
Publication of IL307762A publication Critical patent/IL307762A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL307762A 2021-04-20 2022-04-20 Vaccine against viruses IL307762A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2021060273 2021-04-20
PCT/EP2022/060417 WO2022223617A1 (en) 2021-04-20 2022-04-20 Virus vaccine

Publications (1)

Publication Number Publication Date
IL307762A true IL307762A (en) 2023-12-01

Family

ID=81579467

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307762A IL307762A (en) 2021-04-20 2022-04-20 Vaccine against viruses

Country Status (11)

Country Link
US (1) US20240383947A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326317A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024517642A (cg-RX-API-DMAC7.html)
KR (1) KR20240009419A (cg-RX-API-DMAC7.html)
CN (1) CN117750974A (cg-RX-API-DMAC7.html)
AU (1) AU2022260466A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021654A2 (cg-RX-API-DMAC7.html)
CA (1) CA3215771A1 (cg-RX-API-DMAC7.html)
IL (1) IL307762A (cg-RX-API-DMAC7.html)
MX (1) MX2023012368A (cg-RX-API-DMAC7.html)
WO (1) WO2022223617A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN117153245B (zh) * 2023-10-18 2024-03-19 无锡市疾病预防控制中心 预测新型冠状病毒S蛋白RBD区域与hACE2受体相互作用的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
DK2046826T3 (da) 2006-07-24 2011-10-24 Biorexis Pharmaceutical Corp Exendin-fusionsproteiner
US20100113339A1 (en) 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
AU2008345424A1 (en) 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
CN102076713B (zh) 2008-05-02 2015-03-25 诺华股份有限公司 改进的基于纤连蛋白的结合分子及其用途
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
WO2011051478A1 (en) 2009-10-30 2011-05-05 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
DK2558491T3 (en) 2010-04-13 2018-10-15 Bristol Myers Squibb Co Fibronectin-based Scaffold domain proteins that bind PCSK9
EP2758436B1 (en) 2011-09-23 2019-06-12 Universität Stuttgart Serum half-life extension using immunoglobulin binding domains
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
MA46023A (fr) * 2015-10-22 2019-07-03 Modernatx Inc Vaccin contre le virus de la grippe à large spectre

Also Published As

Publication number Publication date
KR20240009419A (ko) 2024-01-22
CN117750974A (zh) 2024-03-22
AU2022260466A9 (en) 2023-11-16
JP2024517642A (ja) 2024-04-23
US20240383947A1 (en) 2024-11-21
CA3215771A1 (en) 2022-10-27
MX2023012368A (es) 2023-11-01
AU2022260466A1 (en) 2023-11-02
WO2022223617A1 (en) 2022-10-27
EP4326317A1 (en) 2024-02-28
BR112023021654A2 (pt) 2023-12-26

Similar Documents

Publication Publication Date Title
EP1084261B1 (en) Recombinant venezuelan equine encephalitis virus vaccine
JP2005511076A5 (cg-RX-API-DMAC7.html)
EP2391383B1 (en) Codon-optimized hepatitis b virus core antigen (hbcag)
CN106167518B (zh) 截短的轮状病毒vp4蛋白及其用途
CN107384943B (zh) 柯萨奇病毒a6病毒样颗粒在昆虫细胞中的制备及其应用
CN1653085A (zh) Hiv调节/辅助蛋白的融合蛋白
MXPA05005140A (es) Vacuna contra el virus del nilo occidental.
US20250339511A1 (en) Nucleic acid vaccine against monkeypox virus and use thereof
WO2011150745A1 (zh) 结核杆菌ag85ab嵌合基因疫苗、其制备方法及应用
JP2024517642A5 (cg-RX-API-DMAC7.html)
KR20200070302A (ko) 치주염 백신 및 관련 조성물 및 사용 방법
KR102675879B1 (ko) SARS-CoV-2 스파이크 단백질 S1 유래 단백질 및 페리틴 유래 단백질을 포함하는 재조합 단백질 및 이의 용도
KR20240009981A (ko) 아미노산, 뉴클레오티드 및 이를 발현하는 벡터, 및 사르베코바이러스 감염을 예방하는 데에 있어서의 이의 용도
CN117321069A (zh) 基于减毒呼肠孤病毒的疫苗组合物及其用途
WO2003102025A1 (en) Protein inducing cell death of helicobacter pylori
WO2002018600A1 (en) Groes and groel homologs of francisella tularensis
KR100430960B1 (ko) 매우약독화된재조합일본뇌염바이러스를생성하는감염성일본뇌염바이러스cDNA클론및이의백신
US20240382584A1 (en) Hbv vaccine inducing pres-specific neutralizing antibodies
JPH08198774A (ja) Dnaワクチン
JP2024518565A (ja) 組換え重複ペプチド及びネイティブタンパク質を含むワクチン製剤
JPH0515376A (ja) キメラインフルエンザ−hivワクチン
Chamcha Probiotics based approaches to target mucosal compartments: Potential novel approaches to HIV vaccine development
KR20240054479A (ko) 바이러스 표면 엔지니어링 기반의 면역 증강된 돼지 유행성 설사병 바이러스 백신
US20160215023A1 (en) Simple vaccines from dna launched suicidal flaviviruses
Weaver From viruses to vanguard vaccines: the development of vaccination